OncoSec Medical Incorporated (ONCS)

NASDAQ: ONCS · IEX Real-Time Price · USD
0.739
0.004 (0.61%)
May 18, 2022 4:30 PM EDT - Market closed
Market Cap29.08M
Revenue (ttm)n/a
Net Income (ttm)-40.95M
Shares Out39.35M
EPS (ttm)-1.06
PE Ration/a
Forward PE8.67
Dividendn/a
Ex-Dividend Daten/a
Volume14,661
Open0.770
Previous Close0.734
Day's Range0.730 - 0.770
52-Week Range0.670 - 4.250
Beta1.97
AnalystsBuy
Price Target7.65 (+935.3%)
Earnings DateJun 10, 2022

About ONCS

OncoSec Medical Incorporated, a late-stage immuno-oncology company, focuses on designing, developing, commercializing intra-tumoral DNA-based therapeutics to stimulate and augment anti-tumor immune responses for the treatment of cancer. The company's lead product candidate is ImmunoPulse IL-12 that uses electroporation device to deliver a DNA-encoded interleukin-12 for reversing the immunosuppressive microenvironment in the treated tumor. It is also developing ImmunoPulse IL-12 with KEYTRUDA in patients with advanced melanoma that is in clinica...

IndustryBiotechnology
Founded2008
CEODaniel O'Connor
Employees54
Stock ExchangeNASDAQ
Ticker SymbolONCS
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 8 analysts, the average rating for ONCS stock is "Buy." The 12-month stock price forecast is 7.65, which is an increase of 935.32% from the latest price.

Price Target
$7.65
(935.32% upside)
Analyst Consensus: Buy
Stock Forecasts

News

OncoSec Appoints Dr. Robert Arch as President and Chief Executive Officer

PENNINGTON, N.J. and SAN DIEGO , April 29, 2022 /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ: ONCS) (the "Company" or "OncoSec"), a clinical-stage biotechnology company focused on developing int...

2 weeks ago - PRNewsWire

OncoSec Announces Appointment of George Chi as Chief Financial Officer

PENNINGTON, N.J. and SAN DIEGO, Feb. 22, 2022 /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ: ONCS) (the "Company" or "OncoSec"), a clinical-stage biotechnology company focused on developing intra...

2 months ago - PRNewsWire

OncoSec Announces Changes to its Board of Directors

PENNINGTON, N.J. and SAN DIEGO, Dec. 17, 2021 /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ: ONCS) (the "Company" or "OncoSec"), a clinical-stage biotechnology company focused on developing cytok...

5 months ago - PRNewsWire

OncoSec Medical Hosting SITC Key Opinion Leader Webinar on Updated Data from the KEYNOTE-695 Study

PENNINGTON, N.J. and SAN DIEGO, Nov. 2, 2021 /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ: ONCS) will host a conference call and webcast for investors and analysts on Friday, November 12 at 7:00...

6 months ago - PRNewsWire

OncoSec Provides Business Update

PENNINGTON, N.J. and SAN DIEGO, Oct. 20, 2021 /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ: ONCS) (the "Company" or "OncoSec"), a clinical-stage biotechnology company focused on developing cytok...

6 months ago - PRNewsWire

5 Top Penny Stocks Analysts Say To Buy With 119%-430% Price Targets

5 Penny Stocks To Buy According To Analysts The post 5 Top Penny Stocks Analysts Say To Buy With 119%-430% Price Targets appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks....

Other symbols:ENDPKOSSESNWTRH
7 months ago - PennyStocks

OncoSec Provides Leadership Update

PENNINGTON, N.J. and SAN DIEGO, Aug. 16, 2021 /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec") today announced the establishment of a Leadership Committee consisti...

9 months ago - PRNewsWire

OncoSec to Participate in Fireside Chat at BTIG Virtual Biotechnology Conference

PENNINGTON, N.J. and SAN DIEGO, July 26, 2021 /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec") today announced that Interim CEO and Chief Operating Officer, Brian ...

9 months ago - PRNewsWire

Top Penny Stocks to for Your Buy List Right Now? Here's 9 to Watch

Are these top penny stocks on your watchlist right now? The post Top Penny Stocks to for Your Buy List Right Now?

10 months ago - PennyStocks

Why Shares Of OncoSec Medical Are Trading Higher Today

OncoSec Medical (NASDAQ: ONCS) shares are trading higher after the company announced it entered into a Clinical Trial Collaboration and Supply Agreement with Merck to evaluate the combination of OncoSec...

10 months ago - Benzinga

OncoSec Enters into a Collaboration Agreement with Merck for a Pivotal Global Phase 3 Study, KEYNOTE-C87, of TAVO™ Co...

PENNINGTON, N.J. and SAN DIEGO, July 6, 2021 /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec") today announced it has entered into a Clinical Trial Collaboration an...

10 months ago - PRNewsWire

OncoSec Appoints Brian Leuthner as Interim Chief Executive Officer

PENNINGTON, N.J. and SAN DIEGO, June 24, 2021 /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec") today announced that Daniel O'Connor has resigned and that Brian Leu...

10 months ago - PRNewsWire

OncoSec Appoints Industry Leading Electroporation Device Expert, Jeffrey Silverman, as Vice President of Product Engi...

PENNINGTON, N.J. and SAN DIEGO, June 14, 2021 /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec"), today announced the appointment of Jeffrey Silverman as Vice Presid...

11 months ago - PRNewsWire

OncoSec to Present at the Raymond James Human Health Innovation Conference

PENNINGTON, N.J. and SAN DIEGO, May 27, 2021 /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec") today announced that management will present a company overview at th...

11 months ago - PRNewsWire

OncoSec Appoints Robert M. Schinagl, Ph.D.

PENNINGTON, N.J. and SAN DIEGO, May 17, 2021 /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec") today announced the appointment of Robert M.

1 year ago - PRNewsWire

OncoSec to Present Encore Interim Data from the KEYNOTE-695 Phase 2b Clinical Trial at the 10th World Congress of Mel...

PENNINGTON, N.J. and SAN DIEGO, April 15, 2021 /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec"), a biotechnology company focused on cytokine-based intratumoral imm...

1 year ago - PRNewsWire

OncoSec Receives CE Mark Certification for its Commercial Electroporation Device "GenPulse™" for the Treatment of Sol...

PENNINGTON, N.J. and SAN DIEGO, April 14, 2021 /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec"), a biotechnology company focused on cytokine-based intratumoral imm...

1 year ago - PRNewsWire

OncoSec Medical Sponsoring KOL Webinar On A High Unmet Medical Need: Anti-PD-1 Checkpoint Refractory Metastatic Melanoma

PENNINGTON, N.J. and SAN DIEGO, March 25, 2021 /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec"), a biotechnology company focused on cytokine-based intratumoral can...

1 year ago - PRNewsWire

OncoSec Appoints Bridget O'Keeffe, Ph.D. as Vice President of Clinical Development

PENNINGTON, N.J. and SAN DIEGO, Feb. 18, 2021 /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec") today announced the appointment of Bridget O'Keeffe, Ph.D., a biotec...

1 year ago - PRNewsWire

OncoSec Announces First Subjects Dosed in Phase 1 Trial of CORVax12, OncoSec's COVID-19 Vaccine Candidate Combining I...

PENNINGTON, N.J. and SAN DIEGO, Jan. 27, 2021 /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ: ONCS) today announced that it has dosed several subjects in its Phase 1 clinical trial of CORVax12, th...

1 year ago - PRNewsWire

OncoSec Medical Announces Proposed Public Offering of Common Stock

PENNINGTON, N.J. and SAN DIEGO, Jan. 20, 2021 /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec"), a late-stage biotechnology company focused on designing, developing...

1 year ago - PRNewsWire

OncoSec Announces Exclusive License Agreement for Cliniporator® Gene Electrotransfer Platform Developed by IGEA Clini...

PENNINGTON, N.J. and SAN DIEGO, Nov. 24, 2020 /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec"), a late-stage biotechnology company developing intra-tumoral cancer ...

1 year ago - PRNewsWire

OncoSec Announces Positive Interim Data from KEYNOTE-695 Trial in Anti-PD-1 Checkpoint Refractory Metastatic Melanoma...

PENNINGTON, N.J. and SAN DIEGO, Nov. 9, 2020 /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec") today announced new positive interim data from its KEYNOTE-695 regist...

1 year ago - PRNewsWire

OncoSec Announces Appointment of Sandra Aung, Ph.D. as Senior Vice President, Chief Clinical Development Officer

PENNINGTON, N.J. and SAN DIEGO, Oct. 12, 2020 /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec"), a company developing late- stage intra-tumoral cancer immunotherapi...

1 year ago - PRNewsWire